JP2021523696A5 - - Google Patents

Info

Publication number
JP2021523696A5
JP2021523696A5 JP2020558973A JP2020558973A JP2021523696A5 JP 2021523696 A5 JP2021523696 A5 JP 2021523696A5 JP 2020558973 A JP2020558973 A JP 2020558973A JP 2020558973 A JP2020558973 A JP 2020558973A JP 2021523696 A5 JP2021523696 A5 JP 2021523696A5
Authority
JP
Japan
Prior art keywords
activity
snca
composition according
vector
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020558973A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523696A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/028786 external-priority patent/WO2019209869A2/en
Publication of JP2021523696A publication Critical patent/JP2021523696A/ja
Publication of JP2021523696A5 publication Critical patent/JP2021523696A5/ja
Priority to JP2024019364A priority Critical patent/JP2024073420A/ja
Pending legal-status Critical Current

Links

JP2020558973A 2018-04-23 2019-04-23 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節 Pending JP2021523696A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024019364A JP2024073420A (ja) 2018-04-23 2024-02-13 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862661134P 2018-04-23 2018-04-23
US62/661,134 2018-04-23
US201862676149P 2018-05-24 2018-05-24
US62/676,149 2018-05-24
US201962789932P 2019-01-08 2019-01-08
US62/789,932 2019-01-08
US201962824195P 2019-03-26 2019-03-26
US62/824,195 2019-03-26
PCT/US2019/028786 WO2019209869A2 (en) 2018-04-23 2019-04-23 Downregulation of snca expression by targeted editing of dna-methylation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024019364A Division JP2024073420A (ja) 2018-04-23 2024-02-13 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節

Publications (2)

Publication Number Publication Date
JP2021523696A JP2021523696A (ja) 2021-09-09
JP2021523696A5 true JP2021523696A5 (https=) 2022-05-06

Family

ID=68294262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020558973A Pending JP2021523696A (ja) 2018-04-23 2019-04-23 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節
JP2024019364A Pending JP2024073420A (ja) 2018-04-23 2024-02-13 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024019364A Pending JP2024073420A (ja) 2018-04-23 2024-02-13 Ｄｎａメチル化の標的化された編集によるｓｎｃａ発現の下方調節

Country Status (7)

Country Link
US (1) US20210189361A1 (https=)
EP (1) EP3784785A4 (https=)
JP (2) JP2021523696A (https=)
CN (1) CN112166194A (https=)
AU (1) AU2019261361A1 (https=)
CA (1) CA3097755A1 (https=)
WO (1) WO2019209869A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102922694B1 (ko) 2018-04-19 2026-02-03 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 유전자 편집을 위한 조성물 및 방법
SG11202102012SA (en) * 2018-08-28 2021-04-29 Pharos Vaccine Inc Improved lentiviral vector
SG11202111031RA (en) 2019-04-26 2021-11-29 Allogene Therapeutics Inc Rituximab-resistant chimeric antigen receptors and uses thereof
WO2021007457A1 (en) * 2019-07-09 2021-01-14 Urfer Buchwalder Anne Use of snca-mediated genes for diagnosis and treatment of parkinson's disease
GB202010075D0 (en) * 2020-07-01 2020-08-12 Imp College Innovations Ltd Therapeutic nucleic acids, peptides and uses
JP2024518553A (ja) * 2021-05-13 2024-05-01 フォージ バイオロジクス，インコーポレイテッド アデノウイルスヘルパープラスミド
CN114790463B (zh) * 2022-04-15 2023-10-13 中山大学 稳定转染CRISPR/dCas9系统的单克隆细胞株的构建方法及其应用
EP4342988A1 (en) 2022-09-20 2024-03-27 Eberhard Karls Universität Tübingen, Medizinische Fakultät Compositions and methods for modification of the expression of a snca gene
CN120230839A (zh) * 2025-04-30 2025-07-01 北京凯祥弘康生物科技有限公司 一种检测snca基因dna甲基化水平的引物探针组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014197748A2 (en) * 2013-06-05 2014-12-11 Duke University Rna-guided gene editing and gene regulation
MX374532B (es) * 2013-06-17 2025-03-06 Broad Inst Inc Suministro, uso y aplicaciones terapéuticas de los sistemas y composiciones crispr-cas, para actuar sobre trastornos y enfermedades utilizando componentes víricos.
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
WO2016130600A2 (en) * 2015-02-09 2016-08-18 Duke University Compositions and methods for epigenome editing
US20170035860A1 (en) * 2015-04-02 2017-02-09 Alexander C. Flynn Compositions and methods for treatment of neurogenerative diseases
EP3091087A1 (en) * 2015-05-08 2016-11-09 Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
WO2016205749A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
CA3034369A1 (en) * 2016-08-19 2018-02-22 Whitehead Institute For Biomedical Research Methods of editing dna methylation
EP3585807A1 (en) * 2017-02-22 2020-01-01 CRISPR Therapeutics AG Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders

Similar Documents

Publication Publication Date Title
JP2021523696A5 (https=)
Saito et al. Role of cellular senescence in inflammation and regeneration
Trappe et al. Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study
JP6929791B2 (ja) エピゲノム編集のための組成物および方法
Ge et al. USP1/UAF1-stabilized METTL3 promotes reactive astrogliosis and improves functional recovery after spinal cord injury through m6A modification of YAP1 mRNA
Sides et al. The Epstein-Barr virus latent membrane protein 1 and transforming growth factor–β1 synergistically induce epithelial–mesenchymal transition in lung epithelial cells
JP2019517815A5 (https=)
Yu et al. 1, 25 (OH) 2D3 attenuates pulmonary arterial hypertension via microRNA-204 mediated Tgfbr2/Smad signaling
Zhang et al. Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment
Moreno-Igoa et al. Fragment C of tetanus toxin, more than a carrier. Novel perspectives in non-viral ALS gene therapy
Cuddington et al. Oncolytic bovine herpesvirus type 1 as a broad spectrum cancer therapeutic
Heo et al. Transcriptional profiles of mouse oligodendrocyte precursor cells across the lifespan
Zhao et al. A mesenchymal stem cell aging framework, from mechanisms to strategies
JP2022512974A5 (https=)
Yokota et al. Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma
Wang et al. Role of sphingosine‐1‐phosphate receptors in vascular injury of inflammatory bowel disease
ES2936383T3 (es) Terapias basadas en transcriptasa inversa de la telomerasa para el tratamiento de afecciones asociadas con el infarto de miocardio
CN107137710B (zh) Kindlin-2蛋白作为靶点在制备治疗肾炎的药物中的应用
Heo et al. Transcriptional profiles of murine oligodendrocyte precursor cells across the lifespan
Lavrnja et al. The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis
Lu et al. Bromodomain-containing protein 4 knockdown promotes neuronal ferroptosis in a mouse model of subarachnoid hemorrhage
EP4605519A1 (en) Novel reprogramming method
US5798334A (en) Pharmaceutical compositions for scarless tissue repair and regeneration and methods related thereto
Wang et al. Pemphigus vulgaris: An evidence-based treatment update
Sengun et al. Senolytic Reduction of Senescent Cells Mitigates Atrial Arrhythmia Vulnerability in Aging Rabbits